Shire’s gene therapy candidate SHP654, an investigational factor VIII (FVIII) gene therapy for the treatment of haemophilia A, has been awarded Orphan Drug Designation by US regulators
Shire has submitted a request to the US Food and Drug Administration to test its investigational factor VIII (FVIII) gene therapy SHP654 in patients with the bleeding disorder haemophilia A.